Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial

In this study, researchers tested a new drug called CVN424, which targets a specific pathway in the brain to help reduce "OFF-time" in people with Parkinson's disease (PD). The study involved 141 participants who were already on a stable dose of levodopa and had at least two hours of OFF-time each day. They were randomly assigned to receive either a low dose (50 mg) or a higher dose (150 mg) of CVN424, or a placebo (a non-active treatment) for 28 days. The main goals were to check how safe the drug was and whether it helped reduce OFF-time. The findings showed that treatment with CVN424 was generally safe and well-tolerated. The most common side effects reported were mild headaches and nausea, but there were no serious treatment-related side effects. By the end of the study, participants taking the higher dose of CVN424 experienced an average reduction of 1.6 hours in their OFF-time, compared to 0.5 hours for those on placebo. This difference was statistically significant, indicating that the drug had a meaningful effect. Overall, this study suggests that CVN424 could be a promising option for managing OFF-time in people with PD, supporting further development of this treatment.